Immuneering Corporation (IMRX)

Immuneering Statistics

Total Valuation

Immuneering has a market cap or net worth of $143.94 million. The enterprise value is $115.40 million.

Market Cap	143.94M
Enterprise Value	115.40M

Important Dates

The next estimated earnings date is Tuesday, August 5, 2025, after market close.

Earnings Date	Aug 5, 2025
Ex-Dividend Date	n/a

Share Statistics

Immuneering has 35.99 million shares outstanding. The number of shares has increased by 8.14% in one year.

Current Share Class	35.99M
Shares Outstanding	35.99M
Shares Change (YoY)	+8.14%
Shares Change (QoQ)	+14.43%
Owned by Insiders (%)	24.40%
Owned by Institutions (%)	12.58%
Float	27.21M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	3.53
P/TBV Ratio	4.23
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 7.48, with a Debt / Equity ratio of 0.10.

Current Ratio	7.48
Quick Ratio	7.02
Debt / Equity	0.10
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -102.48% and return on invested capital (ROIC) is -62.22%.

Return on Equity (ROE)	-102.48%
Return on Assets (ROA)	-57.90%
Return on Invested Capital (ROIC)	-62.22%
Return on Capital Employed (ROCE)	-140.94%
Revenue Per Employee	n/a
Profits Per Employee	-$935,984
Employee Count	66
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +236.13% in the last 52 weeks. The beta is 0.37, so Immuneering's price volatility has been lower than the market average.

Beta (5Y)	0.37
52-Week Price Change	+236.13%
50-Day Moving Average	2.74
200-Day Moving Average	2.05
Relative Strength Index (RSI)	58.63
Average Volume (20 Days)	974,796

Short Selling Information

The latest short interest is 1.72 million, so 4.79% of the outstanding shares have been sold short.

Short Interest	1.72M
Short Previous Month	893,835
Short % of Shares Out	4.79%
Short % of Float	6.34%
Short Ratio (days to cover)	0.64

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-64.23M
Pretax Income	-56.07M
Net Income	-61.77M
EBITDA	-63.85M
EBIT	-64.23M
Earnings Per Share (EPS)	-$1.96

Balance Sheet

The company has $35.87 million in cash and $4.08 million in debt, giving a net cash position of $31.78 million or $0.88 per share.

Cash & Cash Equivalents	35.87M
Total Debt	4.08M
Net Cash	31.78M
Net Cash Per Share	$0.88
Equity (Book Value)	41.84M
Book Value Per Share	1.16
Working Capital	33.10M

Cash Flow

In the last 12 months, operating cash flow was -$53.59 million and capital expenditures -$56,342, giving a free cash flow of -$53.65 million.

Operating Cash Flow	-53.59M
Capital Expenditures	-56,342
Free Cash Flow	-53.65M
FCF Per Share	-$1.49

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Immuneering does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-8.14%
Shareholder Yield	-8.14%
Earnings Yield	-41.97%
FCF Yield	-36.45%

Analyst Forecast

The average price target for Immuneering is $13.25, which is 231.25% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$13.25
Price Target Difference	231.25%
Analyst Consensus	Strong Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-68.00%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1